Market Closed -
Japan Exchange
02:00:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
788
JPY
|
0.00%
|
|
+1.03%
|
-9.84%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,202
|
2,243
|
11,881
|
9,157
|
6,317
|
5,343
|
Enterprise Value (EV)
1 |
6,887
|
6,006
|
16,909
|
13,380
|
10,426
|
10,025
|
P/E ratio
|
15
x
|
32
x
|
46.8
x
|
6.68
x
|
9.84
x
|
7.15
x
|
Yield
|
0.53%
|
1.03%
|
0.29%
|
0.76%
|
1.28%
|
1.74%
|
Capitalization / Revenue
|
0.09
x
|
0.1
x
|
0.47
x
|
0.3
x
|
0.21
x
|
0.18
x
|
EV / Revenue
|
0.3
x
|
0.25
x
|
0.67
x
|
0.43
x
|
0.35
x
|
0.33
x
|
EV / EBITDA
|
29.7
x
|
31.4
x
|
41.9
x
|
8.85
x
|
10.7
x
|
10.6
x
|
EV / FCF
|
-
|
6,901,362
x
|
-16,084,708
x
|
22,871,769
x
|
-63,380,649
x
|
-22,573,531
x
|
FCF Yield
|
-
|
0%
|
-0%
|
0%
|
-0%
|
-0%
|
Price to Book
|
0.58
x
|
0.61
x
|
3.03
x
|
1.72
x
|
1.07
x
|
0.8
x
|
Nbr of stocks (in thousands)
|
5,796
|
5,796
|
5,796
|
5,796
|
5,796
|
5,796
|
Reference price
2 |
380.0
|
387.0
|
2,050
|
1,580
|
1,090
|
922.0
|
Announcement Date
|
6/28/18
|
6/26/19
|
6/24/20
|
6/24/21
|
6/23/22
|
6/21/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
23,257
|
23,595
|
25,091
|
30,872
|
30,091
|
30,403
|
EBITDA
1 |
232
|
191
|
404
|
1,512
|
971
|
948
|
EBIT
1 |
104
|
32
|
232
|
1,306
|
741
|
692
|
Operating Margin
|
0.45%
|
0.14%
|
0.92%
|
4.23%
|
2.46%
|
2.28%
|
Earnings before Tax (EBT)
1 |
149
|
94
|
302
|
1,366
|
943
|
1,035
|
Net income
1 |
147
|
70
|
254
|
1,370
|
642
|
747
|
Net margin
|
0.63%
|
0.3%
|
1.01%
|
4.44%
|
2.13%
|
2.46%
|
EPS
2 |
25.36
|
12.08
|
43.83
|
236.4
|
110.8
|
128.9
|
Free Cash Flow
|
-
|
870.2
|
-1,051
|
585
|
-164.5
|
-444.1
|
FCF margin
|
-
|
3.69%
|
-4.19%
|
1.89%
|
-0.55%
|
-1.46%
|
FCF Conversion (EBITDA)
|
-
|
455.63%
|
-
|
38.69%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
1,243.21%
|
-
|
42.7%
|
-
|
-
|
Dividend per Share
2 |
2.000
|
4.000
|
6.000
|
12.00
|
14.00
|
16.00
|
Announcement Date
|
6/28/18
|
6/26/19
|
6/24/20
|
6/24/21
|
6/23/22
|
6/21/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
4,685
|
3,763
|
5,028
|
4,223
|
4,109
|
4,682
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
20.19
x
|
19.7
x
|
12.45
x
|
2.793
x
|
4.232
x
|
4.939
x
|
Free Cash Flow
|
-
|
870
|
-1,051
|
585
|
-165
|
-444
|
ROE (net income / shareholders' equity)
|
-
|
1.61%
|
6.58%
|
29.6%
|
11.5%
|
11.5%
|
ROA (Net income/ Total Assets)
|
-
|
0.15%
|
1.01%
|
4.99%
|
2.7%
|
2.36%
|
Assets
1 |
-
|
48,011
|
25,134
|
27,455
|
23,750
|
31,665
|
Book Value Per Share
2 |
650.0
|
632.0
|
676.0
|
917.0
|
1,019
|
1,147
|
Cash Flow per Share
2 |
88.50
|
134.0
|
212.0
|
199.0
|
195.0
|
227.0
|
Capex
1 |
50
|
118
|
130
|
129
|
439
|
210
|
Capex / Sales
|
0.21%
|
0.5%
|
0.52%
|
0.42%
|
1.46%
|
0.69%
|
Announcement Date
|
6/28/18
|
6/26/19
|
6/24/20
|
6/24/21
|
6/23/22
|
6/21/23
|
|
1st Jan change
|
Capi.
|
---|
| -9.84% | 29.01M | | +11.84% | 27.79B | | -32.98% | 2.98B | | -15.97% | 2.52B | | +11.90% | 2.34B | | -1.11% | 1.91B | | -13.37% | 1.83B | | -7.78% | 1.39B | | -0.38% | 1.27B | | +4.01% | 1.13B |
Medical Supplies
|